DrugEvidence

Drugs / Misoprostol

Misoprostol

Drug

Misoprostol is a prostaglandin analog medicine used for ulcer prevention and multiple obstetric/gynecologic indications, including abortion regimens and postpartum bleeding contexts. In U.S. products it is marketed as Cytotec and in combinations such as Arthrotec. It is available as an established prescription medicine.

Trials
400
Recruiting
13
Completed
245
With results
49

Last revised

Pipeline

Phase by status

PhaseRecruitingNot yetActiveCompletedTerminatedWithdrawnUnknownTotal
Early Phase 1 2413 10
Phase 1 11911 13
Phase 1/2 112 4
Phase 2 232114 40
Phase 2/3 11614 22
Phase 3 239529 57
Phase 4 416711224 109
Not applicable 513798331 130
Unknown 1716 15

Trials started per year

2021
7
2022
13
2023
17
2024
12
2025
11
2026
9

Conditions studied, by phase

ConditionEarly Phase 1Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Not applicableUnknownTotal
Postpartum Hemorrhage 217381526 62
Abortion, Spontaneous 34238 20
Hemorrhage 21582 18
Abortion, Missed 1241621 17
Abortion, Incomplete 1126 10
Blood Loss, Surgical 3311 8
Dilatation, Pathologic 1214 8
Fetal Membranes, Premature Rupture 143 8
Pre-Eclampsia 12111 6
Myofibroma 41 5

Most active sponsors

#SponsorTrialsPhase 3
1Gynuity Health Projects507
2Cairo University296
3Ain Shams University2516
4Assiut University142
5Aswan University Hospital130
6Ain Shams Maternity Hospital80
7Stanford University62
8Montefiore Medical Center50
9University of Pennsylvania52
10Aljazeera Hospital40

Most studied interventions

#InterventionTrials
1Misoprostol400
2Mifepristone52
3Oxytocin47
4Dinoprostone19
5carbetocin16
6Tranexamic Acid11
7isosorbide-5-mononitrate9
8Letrozole9
9Alprostadil6
10Vitamin B 64

Evidence

Results reported
20%49 of 245 completed
Published
10.2%25 of 245 completed
Primary endpoint met
35.5%11 of 31 analyses
Median months to report
15

Documents disclosed

Protocol available
23
Statistical analysis plan
22
PubMed citations
86

Trial profile

Median enrollment
148
Median duration
16.9months
Countries
66
Study sites
487

Who is enrolled

Adults
400
Children
95
Older adults
175
Healthy volunteers
195

Median enrollment by phase

Early Phase 1
155
Phase 1
90
Phase 1/2
80
Phase 2
120
Phase 2/3
200
Phase 3
170
Phase 4
150
Not applicable
150
Unknown
118

Where trials run

Egypt
115
United States
78
Pakistan
17
Israel
13
India
10
Turkey (Türkiye)
9
Vietnam
9
Brazil
7
France
7
Sweden
7

Busiest cities

#CityCountryTrials
1CairoEgypt67
2AswānEgypt14
3AsyutEgypt10
4BostonUnited States9
5ChicagoUnited States7
6GizaEgypt7
7Ho Chi Minh CityVietnam7
8The BronxUnited States7
9AnkaraTurkey (Türkiye)6
10PhiladelphiaUnited States6

Terminations

Terminated
28
Withdrawn
10
Stopped for recruitment
3.5%14 of 400 trials

Stated reasons

Recruitment
14
Other / unclear
13
Funding
7
COVID-19
2
Lack of efficacy
1
Regulatory
1

Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.

Recently stopped

TrialStatusStated reasonStopped
NCT04940013 Terminated Terminated Lack of successful recruitment and loss of funding 2025-09-01
NCT03796416 Withdrawn Withdrawn in error 2025-07-31
NCT06078501 Terminated Terminated Recruitment not feasible for this patient population within study timeframe 2024-07-12
NCT03866772 Terminated Terminated RECRUTIMENT DIFICULTIES 2023-09-24
NCT04768010 Withdrawn Withdrawn After significant delays study was never initiated. No participants enrolled 2023-09-18
NCT05119439 Terminated Terminated Enrollment 2023-06-30
NCT03435458 Terminated Terminated interim analyses 2023-02-02
NCT02209545 Terminated Terminated The study was prematurely closed due to low enrollment rates. 2022-07-31
NCT04004845 Terminated Terminated Study was temporarily paused due to COVID19 and ultimately terminated at the discretion of the PI 2022-06-01
NCT03617172 Terminated Terminated Low enrollment 2021-09-22

Trial records